Knygos.lt nariams
Knygos.lt nariams
- Išsiųsime per 12–18 d.d.
/images/books/11383844/9781608057993.jpg)
- Autorius: Atta Ur Rahman
- Leidėjas: Bentham Science Publishers
- ISBN-10: 1608057992
- ISBN-13: 9781608057993
- Formatas: 17.8 x 25.4 x 2.4 cm, minkšti viršeliai
- Kalba: Anglų
Frontiers in Clinical Drug Research - Anti-Cancer Agents (el. knyga) (skaityta knyga) | knygos.lt
Atsiliepimai
Aprašymas
Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field. The chapters in this volume have been written by leading experts from the field. The contents of this book include new approaches to cancer therapy, treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors, targeting key signaling pathways in pediatric brain tumors, current status of cladribine in lymphoid and myeloid malignancies, natural anti-cancer products and the mechanisms of telomere and telomerase regulation in hematologic malignancies. The Book series is essential to all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the field. The readers will find these reviews valuable and will certainly trigger further research in the pharmaceutical development of anti-cancer agents.
- Autorius: Atta Ur Rahman
- Leidėjas: Bentham Science Publishers
- ISBN-10: 1608057992
- ISBN-13: 9781608057993
- Formatas: 17.8 x 25.4 x 2.4 cm, minkšti viršeliai
- Kalba: Anglų
Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field. The chapters in this volume have been written by leading experts from the field. The contents of this book include new approaches to cancer therapy, treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors, targeting key signaling pathways in pediatric brain tumors, current status of cladribine in lymphoid and myeloid malignancies, natural anti-cancer products and the mechanisms of telomere and telomerase regulation in hematologic malignancies. The Book series is essential to all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the field. The readers will find these reviews valuable and will certainly trigger further research in the pharmaceutical development of anti-cancer agents.
Atsiliepimai